Atossa Files for FDA Clearance of Recalled Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics said on Tuesday that it has submitted a premarket 510(k) notification with the US Food and Drug Administration for its ForeCYTE breast cancer test device.

The Seattle-based company voluntarily recalled the device in October after FDA voiced concerns about certain actions by Atossa, including the marketing of the device although FDA had not cleared or approved the ForeCYTE device for any indication.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.